On October 20, 2021 Oxilio reported that it signed an exclusive global licensing agreement with TRx Biosciences Ltd, a privately held pharmaceutical development company, for its patent rights and know-how connected with the TRx platform technology (Press release, Oxilio, OCT 20, 2021, View Source [SID1234621599]). Oxilio will use this technology for the development and commercialisation of an optimised compound formulation in the field of cancer treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The TRx technology enables targeted oral drug delivery to specific organs, cells and tissues in cancer using a clinically and commercially proven approach.